Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Eatontown, New Jersey Clinical Trials

A listing of Eatontown, New Jersey clinical trials actively recruiting patient volunteers.

RESULTS

Found (10) clinical trials

Pilot BA Study of New LY03005 vs Pristiq

Twenty (20) eligible subjects will be enrolled and assigned to either LY03005 group or Pristiq group at a 1:1 ratio at one site in the USA.

Phase

1.0 miles

Learn More »

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia Alzheimer's Disease and Healthy Volunteers

Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease, or age comparable healthy volunteers.

Phase

1.0 miles

Learn More »

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

This is a multicenter, Phase 1b, randomized, doubleblind, placebocontrolled parallelgroup trial in adults with mild to moderate AD. The primary endpoint is the change from the baseline CSF Amyloid beta oligomer concentration after dosing with CT1812 versus placebo. The change from baseline will be measured through a number of exploratory ...

Phase

1.0 miles

Learn More »

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

This is an open-label, dose-escalating, non randomized, single-center, phase I study of mesothelin-targeted T cells administered intrapleurally as a single infusion in patients with a diagnosis (histologically or cytologically documented) of MPD from mesothelioma, lung cancer, or breast cancer. The total number of patients studied will depend on the number ...

Phase

6.7 miles

Learn More »

Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

PRIMARY OBJECTIVES: I. To demonstrate safety and feasibility of ipilimumab and nivolumab at the standard doses of drug in solid tumor and relapsed refractory HIV-classical Hodgkin lymphoma (cHL) participants with human immunodeficiency virus (HIV) infection given the possibility of increased toxicity based on immune activation, co-morbidity, or interference with highly ...

Phase

6.7 miles

Learn More »

A Study to Test the Combination of Selinexor (KPT-330) Ixazomib and Dexamethasone in Patients With Myeloma

The purpose of this study is to test the safety of a combination of study drugs called selinexor (KPT-330) and ixazomib (MLN9708) with a low dose of dexamethasone. This study tests different doses of the study drug, selinexor to see which dose is safer in people. Depending on which group ...

Phase

6.7 miles

Learn More »

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

This study will test the recommended dose of AZD5363 (recommended from a previous phase 1 study of the drug) in patients with specific AKT mutations. In patients who have ER positive breast cancer with an AKT mutation, they will also be receiving a standard breast cancer drug called fulvestrant that ...

Phase

6.7 miles

Learn More »

Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)

Sorafenib is a new type of anti-cancer drug. It belongs to a new class of medications known as tyrosine kinase inhibitors. Sorafenib is thought to work against cancer in many ways. It helps decrease blood supply to the tumor. It also blocks some proteins that help the tumor cells to ...

Phase

6.7 miles

Learn More »

Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

This is a phase I study, which tests the safety of different doses of lenvatinib in combination with cetuximab, to see which dose is the safest in people. This study will help find out if lenvatinib and cetuximab is a safe and useful combination for treating patients with HNSCC and ...

Phase

6.7 miles

Learn More »

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

PRIMARY OBJECTIVES: I. To achieve an intratumoral lapatinib (lapatinib ditosylate) concentration of at least 1.5 uM in at least 70% of patients 3 hours after the last dose of pulsatile lapatinib. (Group A) II. To determine the pharmacodynamic (PD) effect of pulsatile lapatinib (at pulsatile maximum tolerated dose [MTD]) on ...

Phase

6.7 miles

Learn More »